aod9604 peptide benefits side effects AOD-9604 Safety Profile: What Clinical Trials Show aod9604 effects on appetite AOD

Earlier oral trial METAOD005 randomized 300 adults with obesity to oral AOD-9604 (1, 5, 10, 20, or 30 mg/day) or placebo for 12 weeks

Studies in mice confirmed that animals lacking beta-3 receptors showed no response to AOD-9604, proving this pathway is essential to the mechanism

These established short-term safety and pharmacology context but were not designed to demonstrate weight loss efficacy

That said, the compound has not been through full Phase III trials or FDA drug approval

DEXA is most accurate but least accessible

The copper peptide supports collagen synthesis and cellular repair while AOD 9604 drives lipolysis